InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Mason Michael B, Vice-Président Senior. Insider active across 2 companies, notably ELI LILLY & Co. In total, 5 reports have been recorded. History available since 9 February 2022. The latest transaction was disclosed on 2 January 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Mason Michael B
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
1,166 shares0Common StockSEC:0001193125-26-004367:0
1,219 shares0Common StockSEC:0001193125-25-328680:0
8,023 shares@ US$345.1269.8% of flowCommon StockSEC:0000059478-23-000055:0
6,690 shares0Common StockSEC:0000059478-23-000035:0
2,612 shares@ US$243.270.0001% mcap50.0% of flowCommon StockSEC:0000059478-22-000044:0
5 of 5 declarations
About Mason Michael B
Michael B. Mason is the Senior Vice President and President of Lilly Diabetes at Eli Lilly & Co. He is responsible for the strategic direction of the Lilly Diabetes division, focusing on the development and marketing of diabetes treatments. Mason plays a crucial role in product innovation and improvement, aiming to enhance patients' lives. His expertise in the pharmaceutical sector is a significant asset for Eli Lilly, contributing to its mission of improving global health.
